Worldwide Allergy Trends Will Expand Needle-Free Treatment Access
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
01 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$31.00
56.4% undervalued intrinsic discount15 Aug
US$13.51
1Y
2.3%7D
-3.7%